The original success of the copyright undeniably revolutionized the pharmaceutical landscape, but betting in companies strongly reliant on generic versions presents a complex picture. Despite early profits were substantial, the end of patents and the rise of cheaper alternatives have diminished the customer base. Thus, a thorough evaluation of curr